6/14/2013

NanoString Technologies, which focuses on molecular diagnostics and translational life sciences systems, looks to obtain up to $77.6 million in an initial public offering. The Seattle company will use part of the proceeds to market its Prosigna Breast Cancer assay.

Related Summaries